RemeGen ADC drug RC108 combined with PD-1 has been approved for the treatment of solid tumors in phase Ⅰb/Ⅱ clinical trial

On June 12, RemeGen Pharmaceuticals (Yantai) Co., Ltd. announced that a phase Ⅰb/Ⅱ clinical study of its self-developed innovative antibody conjugate drug RC108 combined with PD-1 was officially approved by the Drug Review Center of the State Food and Drug Administration, targeting advanced solid tumors with c-Met expression.

The study was designed to evaluate the safety, tolerability, and pharmacokinetics of RC108 in combination with PD-1 in patients with c-MeT-expressing advanced solid tumors.

c-Met is a receptor tyrosine kinase, which can activate a variety of different cell signaling pathways, including cell signaling pathways related to proliferation, motility, migration and invasion, by binding to its ligand hepatocyte growth factor. Studies have shown that abnormal activation of c-Met can promote the development and progression of a variety of cancers, and it is generally considered as a potential drug target for the treatment of a variety of tumors.

RC108 is an ADC drug independently developed by RemeGen. The clinical studies of RC108 for c-MeT-positive advanced solid tumors were approved by the National Food and Drug Administration in November 2020 and the US Food and Drug Administration in December 2022. Last month, RC108 combined with vormetinib or combined with PD-1 in the treatment of non-small cell lung cancer Ⅰb/Ⅱ clinical trials have been launched.